
Ascendis provides update on achondroplasia programmes
Ascendis Pharma has provided updates across its achondroplasia programme, including data from the COACH and ApproaCH trials. Combination therapy update The company announced that treatment with the combination of once-weekly TransCon CNP and once-weekly TransCon hGH has continued to demonstrate durable growth in children with… Read More



